This is a purely administrative filing to correct an omitted disclosure. The sell-to-cover 10b5-1 plans are standard for tax withholding and do not signal insider selling intent. Monitor the next 10-Q for any material changes in financials or operating performance.
Price Chart
Executive Summary
Crescent Biopharma filed a Form 10-Q/A to add previously omitted Rule 10b5-1 trading arrangement disclosures for its CEO, COO, CMO, CSO, CFO, Treasurer, and General Counsel. All seven officers adopted sell-to-cover plans on February 25, 2026, to satisfy tax withholding obligations on equity vesting. No financial statements were amended.
Key Facts
- Amendment corrects an inadvertent omission of Rule 10b5-1 trading arrangement disclosure from the original 10-Q filed April 29, 2026
- Seven officers adopted sell-to-cover 10b5-1 plans on February 25, 2026 for tax withholding on RSU/PSU vesting
- No financial statements, Items 307/308, or Section 906 certifications were amended or included
- Share count as of April 24, 2026: 27,571,935 ordinary shares outstanding
Financial Impact
No financial impact — administrative amendment only; share count for tax withholding is not currently determinable
Risk Factors
- No material risks identified — this is a disclosure-only amendment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-Q/A Filing (Primary) | 0001628280-26-044713 |
| Document: cbio-10qaexhibit312pfo.htm | 0001628280-26-044713 |
| Document: cbio-10qaexhibit311peo.htm | 0001628280-26-044713 |
| Document: 0001628280-26-044713-index-headers.html | 0001628280-26-044713 |
| Document: 0001628280-26-044713-index.html | 0001628280-26-044713 |
| Document: 0001628280-26-044713.txt | 0001628280-26-044713 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $11.84 | awaiting T+60 | — | $12.76 (+7.77%) |
Oct 15, 2026 11d ago | Press Release | $11.84 | awaiting T+60 | — | $12.76 (+7.77%) |
Oct 5, 2026 22d ago | Press Release | $13.94 | awaiting T+60 | — | $12.76 (−8.46%) |
Sep 18, 2026 5w ago | Insider Cluster | $16.25 | awaiting T+60 | — | $12.76 (−21.48%) |
Jul 30, 2026 12w ago | 8-K | $15.02 $12.82 | ▼ −14.65% | ▼ −17.11% | $12.76 (−15.05%) |
Jul 20, 2026 14w ago | Insider Buy | $16.64 $12.91 | ▼ −22.42% | ▼ −26.39% | $12.76 (−23.32%) |
Jul 15, 2026 14w ago | 8-K / 424B5 | $15.11 $14.91 | ▲ +1.32% | ▲ +5.03% | $12.76 (+15.55%) |
Jul 14, 2026 14w ago | Press Release | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $12.76 (+18.57%) |
Jul 14, 2026 14w ago | 424B5 | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $12.76 (+18.57%) |
Jul 13, 2026 15w ago | EFFECT | $15.69 $13.57 | ▼ −13.51% | ▼ −17.51% | $12.76 (−18.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers